CMPX Compass Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1738021 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-31.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-49.0%
ROA-42.6%
ROIC (approx.)-56.2%
Asset turnover—
Leverage & solvency
Liabilities / assets18.3%
Debt / equity0.00x
Current ratio6.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $850,000 |
| R&D expense | $55.97M | $42.34M |
| SG&A expense | $16.87M | $15.13M |
| Operating income | -$72.84M | -$56.62M |
| Income tax | $0 | $0 |
| Net income | -$66.49M | -$49.38M |
| EBITDA | -$72.56M | -$56.04M |
| EPS (basic) | -0.42 | -0.36 |
| EPS (diluted) | — | — |
| Weighted avg. shares (diluted) | — | 137.40M |
| Balance sheet | ||
| Cash & equivalents | $30.64M | $43.48M |
| Short-term investments | $178.26M | $83.24M |
| Current assets | $209.82M | $132.75M |
| PP&E, net | $102,000 | $353,000 |
| Total assets | $219.59M | $140.40M |
| Current liabilities | $13.97M | $8.87M |
| Total liabilities | $22.80M | $15.17M |
| Shareholders' equity | $196.79M | $125.23M |
| Shares outstanding | 178.32M | 137.82M |
| Cash flow statement | ||
| Operating cash flow | -$49.14M | -$44.85M |
| Capital expenditure | $25,000 | $44,000 |
| Free cash flow | -$49.17M | -$44.90M |
| Investing cash flow | -$93.31M | $46.77M |
| Financing cash flow | $129.61M | $17.34M |
| Depreciation & amortization | $276,000 | $589,000 |
| Stock-based compensation | $8.37M | $8.56M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.